Skip to main content

The Administration and Study of COVID-19 Vaccines in Sweden

General information on vaccine research

Over the last two years, the COVID-19 pandemic has challenged societies and healthcare systems worldwide, and vaccines and therapeautic treatments have been rapidly developed in response. To date, the European Medicines Agency (EMA) has approved four vaccines against COVID-19:

  • Comirnaty - produced by Pfizer/BioNTech, approved on 21st December 2020.
  • Spikevax - produced by Moderna, approved on 6th January 2021.
  • Vaxzevria - produced by AstraZeneca, approved on 29th January 2021.
  • Covid-19 Vaccine - produced by Janssen, approved on 11th March 2021.
  • Nuvaxovid - produced by Novavax, approved on 20th December 2021.

As of December 2021, only Comirnaty (Pfizer/BioNTech) and Spikevax (Moderna) are available in Sweden. Vaxzevria (AstraZeneca) was used in past but is no longer used after 1st September 2021.

This page is focussed on vaccine research. On it, we visualise information about the amount of people (across different regions, different age groups, or in Sweden generally) that have received one, two, or three doses of vaccination. We also provide links to the publicly available data underlying those visualisations. The visualisations do not include information about the type of vaccine used.

The section also displays ongoing Swedish research projects related to vaccine research. These projects are focussed broadly on vaccines and, as such, they include life science projects, registery-based projects, and public health projects. We also show a subset of publications related to vaccine research by researchers affiliated with a Swedish University or Research Institute.

We invite researchers affiliated to a Swedish research institute to get in touch with us about adding information about their vaccine research data or visualisations on this page; send us an email to datacentre@scilifelab.se.

Additional resources on COVID-19 vaccines

  • The Swedish Health Agency provides general information about COVID-19 here.
  • The Swedish Medical Products Agency provides information about COVID-19 vaccines here.
  • For health information connected to vaccination and tests by different Swedish Regions, see Regional information on 1177.
  • The European Centre for Disease Prevention and Control (ECDC) shows information about the vaccines here.
  • Information about the vaccines is available from the Centre for disease Control here.
  • Information and data visualisations related to the register-based large-scale national population study to monitor COVID-19 vaccination effectiveness and safety (RECOVAC) are presented in a separate dashboard.
Visualisations on this page last updated: .

The visualisations in this section are based on publicly available data from the Swedish Health Agency (Folkhälsomyndigheten, FoHM). Follow this link to view their summary of statistics related to vaccination against COVID-19 in Sweden (only available in Swedish). The data used to produce the visualations can be downloaded here. For each visualisation, we describe which part of the dataset was used and how the calculations were done. The source data is updated weekly (on Thursdays), and this page will be updated shortly thereafter.

The code used to produce the visulations can be found on GitHub. All data is processed using a single data preparation script. The codes required to generate each plot are linked beneath the visualisations.

General summary statistics

In this section, we examine the overall levels of vaccination in Sweden, as well as the recent rate of vaccination.

Here, we compare two methods of calculation that can be used to determine the percentage of the Swedish population that have received a given vaccination dose level. One method involves calculating the number of vaccines as a percentage of the number of people in the age categories eligible to get a given dose. Individuals born in or before 2009 (at least 12-13 years old) are considered eligible for the first two doses, individuals born in or before 2003 (at least 18-19 years old) are considered eligible for the third dose, and individuals born in or before 1956 (at least 65-66 years old) are considered eligible for the fourth dose. We refer to this method of calculations as the ‘eligible population method’. The other method instead considers the number of people vaccinated as a percentage of the entire population, regardless of how much of the population is eligible. We refer to this method of calculation as the ‘whole population method’.

Please note, because not everyone is eligible for all doses, it would not be appropriate to compare values between the doses for the purposes of asssessing e.g. coverage or uptake.

We display the results of both calculations for each vaccine dose (first, second, third, and fourth) on the chart below to highlight how the method of calculation used influences the measurement. Please note that the doses are sometimes referred to differently elsewhere, with ‘fully vaccinated’ referring to those given 2 or 3 doses, depending on the source, and ‘booster dose’ most often referring to the third dose.

For calculations done using the ‘eligible population method’, we use data from the ‘Vaccinerade tidsserie’ (first two doses), ‘Vaccinerade tidsserie dos 3’ (third dose), and ‘Vaccinerade tidsserie dos 4’ (fourth dose) tabs of the FoHM data, specifically the percentage values. For the ‘whole population method’, we do not take values directly from the data, but instead use the latest data from Statistics Sweden (SCB)) and the most recent ‘raw number’ of the doses administered from the FoHM data.

Note on the graph: Click on the coloured squares in the legend of the below graph to toggle which datasets are displayed. A single click will toggle just the dataset that you clicked on. A double-click on a colour will cause the map to display ONLY the dataset clicked on.

Code used to produce plot: Script to produce plot.

Code used to generate the ‘live text’ in the summary paragraph below: ‘Live text’ script.

To summarise, in total, % of the population that are eligible for the first dose have received at least one dose of vaccination against COVID-19, which represents % of the whole population. The values indicate that % of the eligible population were vaccinated last week (a change in rate of % compared to the previous week), or % of the whole population (a change of % compared to the previous week). By contrast, % of those eligible, and % of the whole population have received at least two doses in total. The values indicate that % of those eligible and % of the whole population received their second dose last week (a change in rate of % and % compared to the previous week, respectively). In total, % of the eligible population received the third (or ‘booster’) dose, representing % of the whole population. This means that % of the eligible population received their third dose last week (a change in rate of % compared to the previous week), or % of the whole population (a change of % compared to the previous week). To date, % of the whole population has received a fourth dose, and % of those eligible. The relatively greater difference between these two calculations for the fourth dose, occurs because only a very small portion of the population is eligible. In the last week, % of the whole population were vaccinated with a fourth dose, a change in rate of % compared to the previous week. By contast, % of the eligible population were vaccinated with a fourth dose, a relative change in rate of % compared to the previous week.

Administration of vaccinations over time

The first vaccine doses were administered in Sweden in early 2021. As with other countries, the first two doses of the vaccination were made available to progressively younger age groups over time. The third dose of the vaccine was first offered in autumn of 2021, and was offered to individuals a given time period after their second dose. In early 2022, a fourth dose was made available to those aged over 80, those receiving care, those living in housing facilities for the elderly, and those with severe immunodeficiency. This was extended to include those over 65 in April 2022.

Time series data on the first and second doses is held sepately than that for other doses in the data available from FoHM). Time series data on the first two doses is available in the ‘Vaccinerade tidsserie’ tab. Time series data about the third dose is available in the ‘Vaccinerade tidsserie dos 3’ tab, and time series data about the fourth dose is available in the ‘Vaccinerade tidsserie dos 4’ tab

Again, please note that it would not be valid to make comparisons across the doses; they are not equally available across all age/risk groups, and FoHM only include doses given to certain age groups in their data. Specifically, only first or second doses administered to those born in or before 2009 (at least 12-13 years old), third doses given to people born in or before 2003 (at least 18-19 years old), and fourth doses given to those born in or before 1956 (at least 65-66 years old) are included.

We have presented the data for the whole of Sweden as a percentage of the Swedish population in the below graph (using the latest population size data from Statistics Sweden (SCB)). Please keep in mind that this data differs from the percentages as calculated by FoHM, who use the ‘eligible population method’. However, the results are comparable to the calculations reported by other countries, see the information in the ‘general summary statistics’ section for details.

Note on the graph: Click on the coloured squares in the legend of the below graph to toggle which datasets are displayed. A single click will toggle just the dataset that you clicked on. A double-click on a colour will cause the map to display ONLY the dataset clicked on.

Code used to produce plot: Script to produce plot.

Administration of vaccinations in each county (län)

In this section, we explore the levels of vaccination coverage for each of the doses in each county (län) of Sweden. For each dose, we have calculated the percentage of the people in the county that have received that dose (using the lastest data from FoHM and Statistics Sweden (SCB)). Data about the numbers of first and second doses administered in each county is taken from the ‘Vaccinerade tidsserie’ tab of the data from FoHM. Again, please note that the ‘raw number’ of first and second vaccine doses administered includes only those given to individuals born in or before 2009 (at least 12-13 years old). As explained in the sections above, there is no directly comparable data regarding the third dose, as only the doses given to people born in or before 2003 (at least 18-19 years old) are included. We have used the ‘Totalt’ values in the ‘Dos 3 per åldersgrupp’ tab of the data from FoHM) for this calculation. It is exactly equivalent to the number given in the time series data for the third dose. As with the third dose, data for the fourth dose is not directly comparable to that from any other dose. Indeed, the number of ‘fourth doses’ administered only includes those given to people born in or before 1956 (at least 65-66 years of age). This is obviously a much smaller portion of the population compared to any of the other three doses. As a result, we find it appropriate to consider the data in two ways; one in which the ‘whole population method’ for calculation is used, and one in which the ‘eligible population method’ is used. This will allow a clearer understanding of the differences between län in terms of the coverage for this dose. The data were taken from the ‘Dos 4 per åldersgrupp’ tab of the data from FoHM). The ‘Totalt’ value was used for the ‘whole population method’, and the percantage calculation was used for the ‘eligible population method’.

Again, please note that percentage values calculated using the ‘whole population method’ will differ from those calculated by FoHM, whose calculations do not consider the whole population, but rather the population eligible for the dose (from 12-13 years for the first and second doses, from 18-19 years for the third dose, and from 65-66 years for the fourth dose).

Administration of one vaccine dose

Code used to produce plot: Script to produce maps.

Administration of two vaccine doses

Code used to produce plot: Script to produce maps.

Administration of three vaccine doses

Code used to produce plot: Script to produce maps.

Administration of four vaccine doses

Code used to produce plot: Script to produce maps.

Administration of vaccinations according to age group

We constructed the below heatmap to show how the relative numbers of people vaccinated differs according to age. Unsurprisingly, the more advanced age groups tend to have higher levels of vaccination for each dose, as they are typically given access at an earlier date.

Data is available for individuals born in or before 2009 (i.e. at least 12-13 years old) for the first and second vaccine doses (available in the ‘Vaccinerade ålder’ tab of the data from FoHM), and for people born in or before 2003 (i.e. at least 18-19 years old) for the third dose (available in the ‘Dos 3 per åldersgrupp’ tab of the data from FoHM). For the fourth dose, data is only available for those born in or before 1956 (i.e. at least 65-66 years old) available in the ‘Dos 4 per åldersgrupp’ tab of the data from FoHM). This means that data is not available for all age groups for each dose, and this is reflected in the plot. In this case, we have not performed any recalculation of the data, so the numbers are the same as those provided by FoHM (i.e. all values were calculated using the ‘eligible population method’).

Please note, data has not been added for 65-69 year olds for the fourth dose because data is not available in equivalent categories.

Note about the heatmap: A white colouration indicates that no data is available for that age group.

Code used to produce plot: Script to produce heatmap.

Ongoing research projects

Below is a manually curated overview of projects focussed on vaccine research that are/were funded by major funding agencies in Sweden. As it is manually curated, the list may not be exhaustive, but new projects will be added as soon as possible. If you are aware of a project that is not listed here but ought to be, please get in touch with us. For a list of all research projects funded by major funding agencies in Sweden, see this section of the portal instead.

Project title Principal investigator PI affiliation Funder
The immunology of adverse events to SARS-CoV-2 vaccines Petter Brodin Karolinska Institute SciLifeLab / Knut and Alice Wallenberg Foundation
Register-based large-scale national population study to monitor Covid-19 vaccination effectiveness and safety (RECOVAC) Fredrik Nyberg University of Gothenburg SciLifeLab / Knut and Alice Wallenberg Foundation
The Stockholm 65PLUS cohort- A prospective longitudinal study of immune responses induced after Covid-19 vaccination Anna-Lena Spetz Stockholm University SciLifeLab / Knut and Alice Wallenberg Foundation
Impact of immune suppressants on SARS-CoV 2 vaccination responses Fredrik Piehl Karolinska Institute SciLifeLab / Knut and Alice Wallenberg Foundation
SARS-CoV-2 infections in relation to vaccination among healthcare workers of the Stockholm Region Joakim Dillner Karolinska Institute SciLifeLab / Knut and Alice Wallenberg Foundation
Immune responses to COVID-19 vaccination in unexposed, previously infected and immunosuppressed individuals Anna Lundgren University of Gothenburg SciLifeLab / Knut and Alice Wallenberg Foundation
CoVASC - Covid Vaccination Antibody structural correlates Johan Malmström Lund University SciLifeLab / Knut and Alice Wallenberg Foundation
Covid-19 vaccination in immunocompromised individuals: An interdisciplinary framework to gain mechanistic insight into durable immunity to SARS-CoV-2 infection Soo Aleman Karolinska Institute SciLifeLab / Knut and Alice Wallenberg Foundation
Efficacy and immunogenicity of a SARS-CoV-2 vaccine in highly immunocompromised recipients of CAR T cell therapy and allogeneic stem cell transplantation Karin Loré Karolinska Institute SciLifeLab / Knut and Alice Wallenberg Foundation
High Resolution Analysis of Vaccine-Induced Responses in SARS-CoV-2 Experienced Individuals Mattias Forsell Umeå University SciLifeLab / Knut and Alice Wallenberg Foundation
Antibody specificities for protective immunity after Covid-19 vaccination Karin Loré Karolinska Institute Swedish Research Council
Ryktesspridning och tillit bland vaccinskeptiska grupper i Sverige Sibylle Herzig van Wees Karolinska Institute Forte
Rollen för MAIT celler i COVID-19 immunpatogenes och mRNA vaccin responsen Johan Sanberg Karolinska Institutet Swedish Research Council
Design and development of mucosal vaccine vectors in commensal bacteria expressing SARS-CoV-2 antigens as a potential prophylactic method Lars Engstrand Karolinska Institute Swedish Research Council
Rapid therapy development through Open Coronavirus Vaccine Platform Matti Sällberg, Gustaf Ahlén Karolinska Institute Horizon 2020
COVID-19 Vaccine Effect, Response and Safety (COVERS) Sweden: Clinical and epidemiological studies with particular focus on vulnerable groups Clas Ahlm Umeå University Swedish Research Council
Register studies and immunological effect studies of COVID-19 vaccination and build-up of infrastructure for pandemic preparedness at national level (RE-VISION) Magnus Gisslén University of Gothenburg Swedish Research Council
FASTER – National COVID-19 vaccine research platform Pontus Naucler Karolinska Institute Swedish Research Council
Real time evaluation of COVID-19 vaccination in Swedish healthcare regions based on an information platform that supports system modelling and machine learning Thomas Schön Linköping University Swedish Research Council
Epidemiological, immunological and genetic mapping of side effects of COVID-19 vaccines Mia Wadelius Uppsala University Swedish Research Council

Publications

Below is a subset of preprints and published scientific journal articles on the subject of vaccine research involving at least one author affiliated with a Swedish university or research institute. If you would like for your publication to be displayed here, or feel that information about a publication requires correction, please get in touch with us. For a full list of all publications related to COVID-19 and SARS-CoV-2 that involve at least one author affiliated with a Swedish university or research institute, please see this section of the portal.

Publication Published
Vaccine based on folded RBD-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.
Gattinger P, Kratzer B, Tulaeva I, Niespodziana K, Ohradanova-Repic A, Gebetsberger L, Borochova K, Garner-Spitzer E, Trapin D, Hofer G, Keller W, Baumgartner I, Tancevski I, Khaitov M, Karaulov A, Stockinger H, Wiedermann U, Pickl WF, Valenta R
Allergy. DOI: 10.1111/all.15305
2022-03-31
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.
Nordström P, Ballin M, Nordström A
Lancet Infect Dis. DOI: 10.1016/S1473-3099(22)00143-8
2022-03-31
Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities – surveillance results from southern Sweden, July 2021 to January 2022
Kahn F, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M, Björk J
Euro Surveill 27 (9). DOI: 10.2807/1560-7917.es.2022.27.9.2200121
2022-03-03
Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic haematopoietic stem cell transplantation.
Einarsdottir S, Martner A, Nicklasson M, Wiktorin HG, Arabpour M, Törnell A, Vaht K, Waldenström J, Ringlander J, Bergström T, Brune M, Hellstrand K, Ljungman P, Lagging M
Haematologica. DOI: 10.3324/haematol.2021.280494
2022-03-03
High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?
Xu X, Vesterbacka J, Aleman S, Nowak P, COVAXID Study Group
AIDS 36 (3) 479-481. DOI: 10.1097/QAD.0000000000003135
2022-03-01
Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination.
Kaku CI, Champney ER, Normark J, Garcia M, Johnson CE, Ahlm C, Christ W, Sakharkar M, Ackerman ME, Klingström J, Forsell MNE, Walker LM
Science eabn2688. DOI: 10.1126/science.abn2688
2022-02-10
Status of Planned and Ongoing Paediatric Trials Investigating COVID-19 Vaccines: A Cross-Sectional Study of Paediatric Clinical Trials Planned in Agreed PIPs and/or Registered in Clinical Trial Databases.
Christiansen H, Thirstrup S, Hallgreen CE
Ther Innov Regul Sci. DOI: 10.1007/s43441-021-00356-y
2022-02-07
Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden
Nordström P, Ballin M, Nordström A
Lancet. DOI: 10.1016/s0140-6736(22)00089-7
2022-02-00
T cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial.
Blixt L, Wullimann D, Aleman S, Lundin J, Chen P, Gao Y, Cuapio A, Akber M, Lange J, Rivera-Ballesteros O, Buggert M, Ljunggren H, Hansson L, Österborg A
Haematologica. DOI: 10.3324/haematol.2021.280300
2022-01-20
Novel universal SARS-CoV DNA vaccine inducing neutralizing antibodies to huCoV-19/WH01, Beta, Delta and Omicron variants and T cells to Bat-CoV
Appelberg KS, Ahlen G, Nikoyan N, Yan J, Weber S, Larsson O, Höglund U, Aleman S, Weber F, Perlhamre E, Apro J, Gidlund EK, Tuvesson O, Cadossi M, Salati S, Tegel H, Hober S, Frelin L, mirazimi a, Sallberg M
Research Square. DOI: 10.21203/rs.3.rs-1276351/v1 preprint
2022-01-20
Healthcare use in 700 000 children and adolescents for six months after covid-19: before and after register based cohort study.
Magnusson K, Skyrud KD, Suren P, Greve-Isdahl M, Størdal K, Kristoffersen DT, Telle K
BMJ 376 e066809. DOI: 10.1136/bmj-2021-066809
2022-01-17
Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2.
Bahnan W, Wrighton S, Sundwall M, Bläckberg A, Larsson O, Höglund U, Khakzad H, Godzwon M, Walle M, Elder E, Strand AS, Happonen L, André O, Ahnlide JK, Hellmark T, Wendel-Hansen V, Wallin RP, Malmstöm J, Malmström L, Ohlin M, Rasmussen M, Nordenfelt P
Front Immunol 12 808932. DOI: 10.3389/fimmu.2021.808932
2022-01-14
Integrated epi-econ assessment of vaccination.
Boppart T, Harmenberg K, Krusell P, Olsson J
J Econ Dyn Control 104308. DOI: 10.1016/j.jedc.2022.104308
2022-01-13
Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals
Healy K, Pin E, Chen P, Söderdahl G, Nowak P, Mielke S, Hansson L, Bergman P, Smith CIE, Ljungman P, Valentini D, Blennow O, Österborg A, Gabarrini G, Al-Manei K, Alkharaan H, Sobkowiak MJ, Yousef J, Mravinacova S, Cuapio A, Xu X, Akber M, Loré K, Hellström C, Muschiol S, Bogdanovic G, Buggert M, Ljunggren HG, Hober S, Nilsson P, Aleman S, Sällberg Chen M
Med (N Y). DOI: 10.1016/j.medj.2022.01.001
2022-01-00
Disease severity related to VOC dominance in unvaccinated SARS-CoV-2 positive adults without risk factors in Sweden
Wahlström E, Bruce D, Bennet Bark AM, Walther S, Hanberger H, Strålin K
. DOI: 10.1101/2021.12.23.21268040 preprint
2021-12-27
Brand-Specific Enhanced Safety Surveillance Study of GSK's Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season.
Dos Santos G, Wang H, Jindal P, Rybo M, Roul H, Pallem S, Eckermann T, Godderis L, Martínez Gómez X, Godard E, Soler M, Yousefi M, Salamanca de la Cueva I, Nwoji U
Infect Dis Ther. DOI: 10.1007/s40121-021-00571-y
2021-12-27
SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population.
Elgendy MO, El-Gendy AO, Alzarea AI, Mahmoud S, Alqahtani SS, Fahmy AM, El-Seedi HR, Sayed AM, Alatawi AD, Abdelrahim MEA, Alanazi AS
Vaccines 10 (1). DOI: 10.3390/vaccines10010018
2021-12-24
Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity.
Rahman M, Irmler M, Keshavan S, Introna M, Beckers J, Palmberg L, Johanson G, Ganguly K, Upadhyay S
Viruses 13 (12). DOI: 10.3390/v13122537 data available
2021-12-17
Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination
Kaku CI, Champney ER, Normark J, Johnson CE, Ahlm C, Sakharkar M, Ackerman ME, Forsell MNE, Walker LM
MedRxiv. DOI: 10.1101/2021.12.13.21267598 preprint
2021-12-14
The profile of the COvid-19 VACcination register SAFEty study in Sweden (CoVacSafe-SE).
Ljung R, Sundström A, Grünewald M, Backman C, Feltelius N, Gedeborg R, Zethelius B
Ups J Med Sci 126. DOI: 10.48101/ujms.v126.8136
2021-12-10
Increasing risk of breakthrough COVID-19 in outbreaks with high attack rates in European long-term care facilities, July to October 2021
Suetens C, Kinross P, Gallego Berciano P, Arroyo Nebreda V, Hassan E, Calba C, Fernandes E, Peralta-Santos A, Casaca P, Shodu N, Dequeker S, Kontopidou F, Pappa L, Kacelnik O, Børseth AW, O’Connor L, Garvey P, Liausedienė R, Valintelienė R, Ernst C, Mossong J, Štefkovičová M, Prostináková Z, Danielsen AC, Mougkou A, Lamb F, Cenciarelli O, Monnet DL, Plachouras D
Euro Surveill 26 (49). DOI: 10.2807/1560-7917.es.2021.26.49.2101070
2021-12-09
To be or not to be vaccinated against COVID-19 - The adolescents' perspective - A mixed-methods study in Sweden.
Nilsson S, Mattson J, Berghammer M, Brorsson AL, Forsner M, Jenholt Nolbris M, Kull I, Lindholm Olinder A, Ragnarsson S, Rullander AC, Rydström LL, Andréia Garcia de Avila M, Olaya-Contreras P
Vaccine X 9 100117. DOI: 10.1016/j.jvacx.2021.100117
2021-12-00
A population-based dataset concerning predictors of willingness to get a COVID-19 vaccine in Iran.
Pakpour AH, Yahaghi R, Ahmadizade S, Fotuhi R, Taherkhani E, Ranjbaran M, Buchali Z, Lin C, Griffiths MD, Broström A
Data Brief 39 107459. DOI: 10.1016/j.dib.2021.107459
2021-12-00
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P, Söderdahl G, Österborg A, Smith CIE, Wullimann D, Vesterbacka J, Lindgren G, Blixt L, Friman G, Wahren-Borgström E, Nordlander A, Gomez AC, Akber M, Valentini D, Norlin A, Thalme A, Bogdanovic G, Muschiol S, Nilsson P, Hober S, Loré K, Chen MS, Buggert M, Ljunggren H, Ljungman P, Aleman S, COVAXID-collaborator group (shown separately)
EBioMedicine 74 103705. DOI: 10.1016/j.ebiom.2021.103705
2021-11-29
COVID-19 vaccination in autoimmune disease (COVAD) survey protocol.
Sen P, Gupta L, Lilleker JB, Aggarwal V, Kardes S, Milchert M, Gheita T, Salim B, Velikova T, Gracia-Ramos AE, Parodis I, O'Callaghan AS, Nikiphorou E, Tan AL, Cavagna L, Saavedra MA, Shinjo SK, Ziade N, Knitza J, Kuwana M, Cagnotto G, Nune A, Distler O, Chinoy H, Aggarwal V, Aggarwal R, COVAD Study Group
Rheumatol Int. DOI: 10.1007/s00296-021-05046-4
2021-11-15
Utilization of health care services before and after media attention about fatal side effects of the AstraZeneca vaccine: a nation-wide register-based event study.
Larsen VB, Grøsland M, Telle K, Magnusson K
BMC Health Serv Res 21 (1) 1229. DOI: 10.1186/s12913-021-07233-2
2021-11-13
Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy.
Lockmer S, Uttervall K, Kashif M, Svärd C, Malmsten K, Fletcher-Torres E, Alici E, Lund J, Nahi H
Am J Hematol 96 (11) E443-E446. DOI: 10.1002/ajh.26348
2021-11-01
Allergen Immunotherapy management during vaccinations: An international survey.
Masieri S, Bachert C, Ojeda P, Kim CK, Carlo C, Giorgio C, Study Group on AIT & Vaccinations
World Allergy Organ J 14 (11) 100601. DOI: 10.1016/j.waojou.2021.100601
2021-11-00
Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database.
Kim MS, Jung SY, Ahn JG, Park SJ, Shoenfeld Y, Kronbichler A, Koyanagi A, Dragioti E, Tizaoui K, Hong SH, Jacob L, Salem JE, Yon DK, Lee SW, Ogino S, Kim H, Kim JH, Excler JL, Marks F, Clemens JD, Eisenhut M, Barnett Y, Butler L, Ilie CP, Shin EC, Il Shin J, Smith L
J Med Virol. DOI: 10.1002/jmv.27424
2021-10-28
Susceptibility of Dog, Hamster, and Mouse Cells to the Replication-Competent Adenovirus 11p E1/E3 Green Fluorescence Protein Vector Has Implications for the Selection of Animal Vaccine Models.
Gokumakulapalle M, Wang L, Mei YF
Front Microbiol 12 698999. DOI: 10.3389/fmicb.2021.698999
2021-10-27
Structural Modeling on the Determinants of Effectiveness of SOPs Containing COVID-19 in Mass Gatherings.
Basit A, Scholz M, Niazi AAK, Qazi TF, Shaukat MZ, Rao ZU, Mahmood A
Front Psychol 12 755221. DOI: 10.3389/fpsyg.2021.755221
2021-10-27
GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults
Lanini S, Capone S, Antinori A, Milleri S, Nicastri E, Camerini R, Agrati C, Castilletti C, Mori F, Sacchi A, Matusali G, Gagliardini R, Ammendola V, Cimini E, Grazioli F, Scorzolini L, Napolitano F, Plazzi MM, Soriani M, De Luca A, Battella S, Sommella A, Contino AM, Barra F, Gentile M, Raggioli A, Shi Y, Girardi E, Maeurer M, Capobianchi MR, Vaia F, Piacentini M, Kroemer G, Vitelli A, Colloca S, Folgori A, Ippolito G, Ottou S, Vita S, Vergori A, D’Abramo A, Petrecchia A, Montaldo C, Scalise E, Grassi G, Casetti R, Bordoni V, Notari S, Colavita F, Meschi S, Lapa D, Bordi L, Murachelli S, Tambasco T, Grillo A, Masone E, Marchioni E, Bardhi D, Porzio O, Cocca F, Murachelli S, Turrini I, Malescio F, Ziviani L, Lawlor R, Poli F, Martire F, Zamboni D, Mazzaferri F
Sci. Transl. Med.. DOI: 10.1126/scitranslmed.abj1996
2021-10-26
Lack of Trust, Insufficient knowledge and Risk denial; an in-depth Understanding of Health workers Barriers to uptake of the Covid-19 vaccine at Iganga Hospital Eastern Uganda, and Mengo Hospital Kampala Uganda
Muhamadi L, Edith N, James W, Tumwesigye NM, Museene SK, Mukakaarisa H, Peterson SS, Ekström AM
. DOI: 10.1101/2021.10.13.21264920 preprint
2021-10-19
Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time
Havervall S, Marking U, Greilert-Norin N, Gordon M, Ng H, Christ W, Phillipson M, Nilsson P, Hober S, Blom K, Klingström J, Mangsbo S, Åberg M, Thålin C
MedRxiv. DOI: 10.1101/2021.10.16.21264948 preprint
2021-10-19
Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients.
Melin J, Svensson MK, Albinsson B, Winqvist O, Pauksens K
BMC Immunol 22 (1) 70. DOI: 10.1186/s12865-021-00458-0
2021-10-19
Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study.
Nordström P, Ballin M, Nordström A
Lancet Reg Health Eur 100249. DOI: 10.1016/j.lanepe.2021.100249
2021-10-18
Adverse events of special interest for COVID-19 vaccines - background incidences vary by sex, age and time period and are affected by the pandemic
Nyberg F, Lindh M, Vanfleteren LEGW, Hammar N, Wettermark B, Sundström J, Santosa A, Kirui BK, Gisslén M
MedRxiv. DOI: 10.1101/2021.10.04.21263507 preprint
2021-10-05
High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population – first results from a cohort study in Southern Sweden
Björk J, Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F
Infect Dis (Lond) 1-6. DOI: 10.1080/23744235.2021.1982144
2021-09-29
Identification of Unique Peptides for SARS-CoV-2 Diagnostics and Vaccine Development by an In Silico Proteomics Approach
Kesarwani V, Gupta R, Vetukuri RR, Kushwaha SK, Gandhi S
Front Immunol 12. DOI: 10.3389/fimmu.2021.725240
2021-09-24
Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS-CoV-2 vaccination.
van de Munckhof A, Krzywicka K, Aguiar de Sousa D, Sánchez van Kammen M, Heldner MR, Jood K, Lindgren E, Tatlisumak T, Putaala J, Kremer Hovinga JA, Middeldorp S, Levi M, Arnold M, Ferro JM, Coutinho JM
Eur J Neurol. DOI: 10.1111/ene.15113
2021-09-18
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
Normark J, Vikström L, Gwon YD, Persson IL, Edin A, Björsell T, Dernstedt A, Christ W, Tevell S, Evander M, Klingström J, Ahlm C, Forsell M
N Engl J Med 385 (11) 1049-1051. DOI: 10.1056/nejmc2110716
2021-09-09
Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021.
Seppälä E, Veneti L, Starrfelt J, Danielsen AS, Bragstad K, Hungnes O, Taxt AM, Watle SV, Meijerink H
Euro Surveill 26 (35). DOI: 10.2807/1560-7917.ES.2021.26.35.2100793
2021-09-00
COVID-19 vaccine uptake among older people in relation to sociodemographic factors –cohort results from southern Sweden
Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F, Björk J
. DOI: 10.1101/2021.08.12.21261981 preprint
2021-08-13
Neutralization of VOCs including Delta one year post COVID-19 or vaccine
Havervall S, Marking U, Gordon M, Ng H, Greilert-Norin N, Lindbo S, Blom K, Nilsson P, Phillipson M, Klingström J, Mangsbo S, Åberg M, Hober S, Thålin C
MedRxiv. DOI: 10.1101/2021.08.12.21261951 preprint
2021-08-12
Initial impact of SARS-Cov-2 vaccination on healthcare workers in Italy- Update on the 28th of March 2021.
Mateo-Urdiales A, Del Manso M, Andrianou X, Spuri M, D'Ancona F, Filia A, Rota MC, Petrone D, Vescio MF, Riccardo F, Bella A, Pezzotti P, Fabiani M
Vaccine 39 (34) 4788-4792. DOI: 10.1016/j.vaccine.2021.07.003
2021-08-09
Swedish Covid-19 Investigation for Future Insights - A Population Epidemiology Approach Using Register Linkage (SCIFI-PEARL).
Nyberg F, Franzén S, Lindh M, Vanfleteren L, Hammar N, Wettermark B, Sundström J, Santosa A, Björck S, Gisslén M
CLEP 13 649-659. DOI: 10.2147/CLEP.S312742
2021-07-30
Vaccine allergy: evidence to consider for COVID-19 vaccines.
Nilsson L, Csuth Á, Storsaeter J, Garvey LH, Jenmalm MC
Curr Opin Allergy Clin Immunol. DOI: 10.1097/ACI.0000000000000762
2021-06-04
DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice
Szurgot I, Hanke L, Sheward DJ, Vidakovics LP, Murrell B, McInerney GM, Liljeström P
Sci Rep 11 (1) 3125. DOI: 10.1038/s41598-021-82498-5
2021-02-04
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
Tian JH, Patel N, Haupt R, Zhou H, Weston S, Hammond H, Logue J, Portnoff AD, Norton J, Guebre-Xabier M, Zhou B, Jacobson K, Maciejewski S, Khatoon R, Wisniewska M, Moffitt W, Kluepfel-Stahl S, Ekechukwu B, Papin J, Boddapati S, Jason Wong C, Piedra PA, Frieman MB, Massare MJ, Fries L, Bengtsson KL, Stertman L, Ellingsworth L, Glenn G, Smith G
Nat Commun 12 (1) 372. DOI: 10.1038/s41467-020-20653-8 data available
2021-01-14